BUSINESS Jubilant Pharmova to transfer unclaimed dividends and shares to IEPF by October 2026 Mar 30, 2026
CORPORATES Jubilant Pharmova appoints Daniel J. O’Connor as CEO of Proprietary novel drugs business Dec 2, 2025
CORPORATES Jubilant Pharmova receives 4 observations from USFDA after Pre-Approval Inspection at Roorkee facility Aug 2, 2025
Jubilant Pharmova Q3 FY25 results: Revenue up 9% YoY to Rs 1822 crore, Net profit surges 52% YoY Jan 31, 2025
Jubilant Pharmova subsidiary Jubilant Biosys acquires 80% stake in JASMIN, expands R&D presence in France Jan 29, 2025
Jubilant Pharmova shares drop 2% after USFDA issues five observations to its US-based unit Jan 17, 2025
Jubilant Pharmova Q2 Results: Net Profit falls 78.73% QoQ to ₹102.5 crore, Revenue grows marginally to ₹1,742.2 crore Oct 25, 2024
Jubilant Pharmova receives “Official Action Indicated” notice from USFDA for Montreal facility Sep 28, 2024
Jubilant Pharmova share price surges 24% this week on receiving ‘VAI’ tag for US facility Sep 14, 2024